Common Contracts
2 similar Joint Commercialization Agreement contracts by Genmab a/S, Seagen Inc.
JOINT COMMERCIALIZATION AGREEMENT by and between GENMAB A/S and SEAGEN INC. Dated as of October 19, 2020Joint Commercialization Agreement • March 29th, 2021 • Genmab a/S • Pharmaceutical preparations • New York
THIS JOINT COMMERCIALIZATION AGREEMENT (this “Agreement”) is made as of October 19, 2020 (the “Effective Date”), by and between GENMAB A/S, a Danish corporation (“Genmab”), and SEAGEN INC. (f/k/a SEATTLE GENETICS, INC.), a Delaware corporation (“SGI”). Genmab and SGI are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties.”
CONFIDENTIAL -vi- [*] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. INDEX OF DEFINED TERMS Adverse Event...Joint Commercialization Agreement • February 12th, 2021 • Seagen Inc. • Biological products, (no disgnostic substances) • New York
